PROMINENT Pemafibrate to Reduce cardiovascular OutcoMes by reducing triglycerides IN patiENts with diabetes

P.I.: Michelle Ratliffe, MD Synopsis- This is a research study to find out if K-877 (also called pemafibrate), the study drug, compared to placebo (a treatment which looks like the medicine but contains no active pemafibrate), lowers cardiovascular (CV) complications (also referred to as “events”), such as heart attack, stroke, and death from these conditions, [...]

2017-10-23T20:14:45-06:00October 23rd, 2017|Categories: Clinical Trials|

Influenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated heart failure (INVESTED)

P.I.: Michelle Ratliffe, MD Synopsis- The purpose of this study is to see if a high-dose influenza (“flu”) vaccine is able to safely reduce heart or lung-related problems compared to the standard-dose flu vaccine. Both the high dose and standard dose flu vaccines called Fluzone® are manufactured by Sanofi Pasteur.

2017-10-23T20:02:18-06:00October 23rd, 2017|Categories: Clinical Trials|

A Phase II, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Pegfilgrastim (Neulasta®) in Patients with Alcoholic Hepatitis.

P.I.: Joseph Alcorn, MD Synopsis- Studying new treatments for alcoholic hepatitis (AH) and investigating the pathophysiology (functional changes) of alcoholic hepatitis (liver inflammation caused by drinking alcohol). The primary purpose of this study is to determine whether treatment with pegfilgrastim (Neulasta®) in addition to prednisolone or pentoxifylline is more effective than treatment with prednisolone or [...]

2017-10-23T19:10:36-06:00October 23rd, 2017|Categories: Clinical Trials|
Go to Top